Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687609 | 0.93 | KMT2A (0.61) | KMT2AEPHX2CASP3CA1CA2 | |
| SCHEMBL10490997 | 0.92 | KMT2A (0.60) | KMT2AEPHX2CASP3 | |
| SCHEMBL793384 | 0.89 | KMT2A (0.85) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29687439 | 0.89 | KMT2A (0.65) | KMT2AEPHX2CASP3CA1CA2 | |
| SCHEMBL31295532 | 0.88 | KMT2A (0.63) | KMT2AEPHX2CASP3CA1CA2 | |
| SCHEMBL1660910 | 0.85 | KMT2A (0.74) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL17971325 | 0.85 | KMT2A (0.74) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL24513667 | 0.85 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL15809775 | 0.84 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL697928 | 0.84 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-11484565-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2022-11-01 | — | — | US | disclosed |
| EP-4021919-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 1433/4885EPHX2 2213/4885CASP3 1938/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | KMT2A 1433/4885EPHX2 2213/4885CASP3 1938/4885 |
| US-11484565-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | KMT2A 1433/4885EPHX2 2213/4885CASP3 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.